CLL Microlearning Series – Video #6: Zanubrutinib’s Cardiovascular Profile
Zanubrutinib’s Cardiovascular Profile
Cardiovascular safety is a key consideration when selecting a BTK inhibitor for CLL patients, many of whom are older and may already have cardiac comorbidities.
In this video, an APP specializing in CLL explains how zanubrutinib compares to other BTK inhibitors and outlines practical steps clinicians can take to evaluate and manage cardiovascular risk.
In This Video, You’ll Learn:
- Why BTK inhibitor–related arrhythmias—especially atrial fibrillation—are a key safety concern
- Comparative rates of atrial fibrillation across BTK inhibitors (ibrutinib 16%, acalabrutinib 9%, zanubrutinib 4%)
- How zanubrutinib’s lower arrhythmia rates support safer use in older adults or those with pre-existing cardiac disease
- How to assess whether a patient’s cardiovascular condition is stable enough for BTK inhibitor therapy
- Medication interactions to review, including anticoagulants and rate-controlling drugs
- Best practices for baseline cardiovascular evaluation, including pre-treatment EKG and cardiology involvement when appropriate